TRANSCRIPT OF ANALYST AND INVESTOR CALL

In accordance with the requirements of Regulation 30 and other applicable Regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), 2015, we hereby notify the schedule of Analyst / Institutional Investor Meeting.

In accordance with the provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company at their meeting held on August 4, 2020 has inter alia, transacted the following business: - To convene the Annual General Meeting (AGM) of the Members of the Company on Tuesday, September 29, 2020. - Appointment of Mr. Kaushal Kamlesh Shah (DIN: 01229038) as an additional Director of the Company, w.e.f. August 04, 2020 until the ensuing Annual General Meeting of the members of the Company to be held in calendar year 2020.

Eris Lifesciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on August 04, 2020, inter alia, duly approved / took on record the following: - Declaration of Interim Dividend of Rs 5.50/- (at the rate of 550%) on each fully paid-up equity share of Re.1/- for the Financial Year 2020-21.

Please find attached financial results of the Company

The Board of Directors of the Company at their meeting held today i.e. August 04, 2020 duly Fixed 14th August, 2020 as the record date to determine the names of the equity shareholders, who shall be entitled to receive the payment towards interim dividend for the financial year 2020-21. The payment of the interim dividend would be made to the eligible shareholders on or before 3rd September, 2020.

Pursuant to the requirement of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached investor presentation based on Financials approved in the board meeting held today .i.e. on 04th August, 2020.